JP4357738B2 - システインリッチなレセプターであるｔｒａｉｎ - Google Patents

システインリッチなレセプターであるｔｒａｉｎ Download PDF

Info

Publication number
JP4357738B2
JP4357738B2 JP2000510863A JP2000510863A JP4357738B2 JP 4357738 B2 JP4357738 B2 JP 4357738B2 JP 2000510863 A JP2000510863 A JP 2000510863A JP 2000510863 A JP2000510863 A JP 2000510863A JP 4357738 B2 JP4357738 B2 JP 4357738B2
Authority
JP
Japan
Prior art keywords
receptor
train
dna molecule
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000510863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002505843A (ja
JP2002505843A5 (https=
Inventor
ユルク チョップ，
キャサリン ヘッション，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2002505843A publication Critical patent/JP2002505843A/ja
Publication of JP2002505843A5 publication Critical patent/JP2002505843A5/ja
Application granted granted Critical
Publication of JP4357738B2 publication Critical patent/JP4357738B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2000510863A 1997-09-12 1998-09-11 システインリッチなレセプターであるｔｒａｉｎ Expired - Fee Related JP4357738B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5863197P 1997-09-12 1997-09-12
US60/058,631 1997-09-12
US8442298P 1998-05-06 1998-05-06
US60/084,422 1998-05-06
PCT/US1998/019030 WO1999013078A1 (en) 1997-09-12 1998-09-11 Cysteine rich receptors-train

Publications (3)

Publication Number Publication Date
JP2002505843A JP2002505843A (ja) 2002-02-26
JP2002505843A5 JP2002505843A5 (https=) 2006-01-05
JP4357738B2 true JP4357738B2 (ja) 2009-11-04

Family

ID=26737837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510863A Expired - Fee Related JP4357738B2 (ja) 1997-09-12 1998-09-11 システインリッチなレセプターであるｔｒａｉｎ

Country Status (9)

Country Link
US (4) US7223852B2 (https=)
EP (2) EP1012282B1 (https=)
JP (1) JP4357738B2 (https=)
AT (1) ATE360032T1 (https=)
AU (2) AU9386398A (https=)
CA (1) CA2301173C (https=)
DE (1) DE69837606T2 (https=)
ES (1) ES2286856T3 (https=)
WO (2) WO1999012963A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
ES2307313T3 (es) * 1997-02-27 2008-11-16 Ono Pharmaceutical Co., Ltd. Nuevos polipeptidos, adn que codifican y utilizan estos polpeptidos.
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO1999012963A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
AU748167B2 (en) * 1997-12-29 2002-05-30 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
EP1710299A3 (en) * 1998-12-30 2007-01-10 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
WO2000049149A1 (fr) * 1999-02-19 2000-08-24 Toshio Kitamura Nouvelles proteines du type recepteurs des tnf
UA75049C2 (uk) 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
AU6928200A (en) * 1999-08-25 2001-03-19 Genome Therapeutics Corporation A transmembrane trap for isolating membrane bound proteins
EP1237921A1 (en) 1999-10-22 2002-09-11 ZymoGenetics, Inc. Umlr polypeptides
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
JP2004501604A (ja) * 2000-02-11 2004-01-22 ジェネティクス　インスティテュート，エルエルシー Ｔｒａｄｅ分子およびそれに関連する使用
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
KR101292961B1 (ko) 2005-02-02 2013-08-02 더 유에이비 리서치 파운데이션 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법
JP4898126B2 (ja) * 2005-02-28 2012-03-14 中外製薬株式会社 Ｔｒｏｙシグナルが阻害されたトランスジェニック非ヒト動物
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP2010917B1 (en) * 2006-04-10 2012-06-27 Trustees of Boston University Melanoma biomarker and methods of uses
US9149220B2 (en) 2011-04-15 2015-10-06 Dexcom, Inc. Advanced analyte sensor calibration and error detection
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
EP2825096B1 (en) 2012-03-16 2023-04-26 Dexcom, Inc. Systems and methods for processing analyte sensor data
DK3928687T3 (da) 2017-10-24 2024-09-30 Dexcom Inc Bærbar indretning med på forhånd forbundet analytsensor
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5965388A (en) 1996-07-09 1999-10-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6261801B1 (en) * 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
ES2307313T3 (es) 1997-02-27 2008-11-16 Ono Pharmaceutical Co., Ltd. Nuevos polipeptidos, adn que codifican y utilizan estos polpeptidos.
CN1624128A (zh) * 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012963A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
US20030027272A1 (en) * 1997-09-18 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2306457A1 (en) 1997-10-18 1999-04-29 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU748167B2 (en) 1997-12-29 2002-05-30 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
AU2472899A (en) 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
AU4818599A (en) 1998-07-06 2000-01-24 Schering Corporation Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
JP2000098232A (ja) * 1998-09-25 2000-04-07 Canon Inc 光学素子及びそれを用いた光学系
WO2000049149A1 (fr) 1999-02-19 2000-08-24 Toshio Kitamura Nouvelles proteines du type recepteurs des tnf
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB9927681D0 (en) 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
JP2004501604A (ja) 2000-02-11 2004-01-22 ジェネティクス　インスティテュート，エルエルシー Ｔｒａｄｅ分子およびそれに関連する使用
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2003013578A1 (en) 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
CA2550117A1 (en) 2003-12-16 2005-06-30 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20070186296A1 (en) 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders

Also Published As

Publication number Publication date
AU738688B2 (en) 2001-09-27
ES2286856T3 (es) 2007-12-01
CA2301173A1 (en) 1999-03-18
EP1012282A1 (en) 2000-06-28
US7402658B2 (en) 2008-07-22
WO1999012963A3 (en) 1999-05-06
EP1012282B1 (en) 2007-04-18
JP2002505843A (ja) 2002-02-26
US20090004188A1 (en) 2009-01-01
ATE360032T1 (de) 2007-05-15
WO1999013078A1 (en) 1999-03-18
AU9386398A (en) 1999-03-29
US7838639B2 (en) 2010-11-23
HK1028417A1 (en) 2001-02-16
CA2301173C (en) 2015-04-14
US20060233792A1 (en) 2006-10-19
US20110158993A1 (en) 2011-06-30
EP1012179A2 (en) 2000-06-28
WO1999012963A2 (en) 1999-03-18
US20030219860A1 (en) 2003-11-27
DE69837606D1 (de) 2007-05-31
DE69837606T2 (de) 2008-02-14
AU9230398A (en) 1999-03-29
US7223852B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
JP4357738B2 (ja) システインリッチなレセプターであるｔｒａｉｎ
US10494416B2 (en) Methods of modulating immune responses using BCMA polypeptide
US7276241B2 (en) Methods of treating a tumor that expresses APRIL by administering BCMA
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
WO1999026977A1 (en) Novel receptors opg-2
CN101371923B (zh) Baff受体(bcma),一种免疫调节剂
HK1028417B (en) Cysteine rich receptors-train
HK1157388A (en) Baff receptor (bcma), an immunoregulatory agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090707

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090805

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120814

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130814

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees